Mabpharm Limited (2181.HK)
HKD 0.3
(-4.76%)
HKD 0.3
(-4.76%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 86.72 Million CNY | -6.51% |
| 2022 | 92.76 Million CNY | 358.65% |
| 2021 | -35.86 Million CNY | 91.93% |
| 2020 | -444.49 Million CNY | 7.99% |
| 2019 | -483.09 Million CNY | -418.37% |
| 2018 | -93.19 Million CNY | -6358.42% |
| 2017 | -1.44 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 119.76 Million CNY | 38.09% |
| 2024 Q2 | 119.76 Million CNY | 41.59% |
| 2023 Q3 | 92.23 Million CNY | -25.82% |
| 2023 Q2 | 124.33 Million CNY | -19.56% |
| 2023 Q1 | 154.56 Million CNY | 66.61% |
| 2023 Q4 | 86.72 Million CNY | -5.97% |
| 2023 FY | 86.72 Million CNY | -6.51% |
| 2022 Q1 | 33.32 Million CNY | 192.91% |
| 2022 FY | 92.76 Million CNY | 358.65% |
| 2022 Q3 | 124.47 Million CNY | 168.28% |
| 2022 Q2 | 46.39 Million CNY | 39.24% |
| 2022 Q4 | 92.76 Million CNY | -25.47% |
| 2021 FY | -35.86 Million CNY | 91.93% |
| 2021 Q4 | -35.86 Million CNY | 19.24% |
| 2021 Q3 | -44.41 Million CNY | 83.53% |
| 2021 Q1 | -274.51 Million CNY | 38.24% |
| 2021 Q2 | -269.68 Million CNY | 1.76% |
| 2020 Q4 | -444.49 Million CNY | 1.88% |
| 2020 FY | -444.49 Million CNY | 7.99% |
| 2020 Q2 | -602.83 Million CNY | 1.12% |
| 2020 Q1 | -609.66 Million CNY | -26.2% |
| 2020 Q3 | -453 Million CNY | 24.85% |
| 2019 Q1 | -875.11 Million CNY | -839.01% |
| 2019 FY | -483.09 Million CNY | -418.37% |
| 2019 Q4 | -483.09 Million CNY | 1.0% |
| 2019 Q3 | -487.96 Million CNY | 43.75% |
| 2019 Q2 | -867.44 Million CNY | 0.88% |
| 2018 FY | -93.19 Million CNY | -6358.42% |
| 2018 Q1 | 76.44 Million CNY | 0.0% |
| 2018 Q4 | -93.19 Million CNY | -16.28% |
| 2018 Q3 | -80.14 Million CNY | 0.0% |
| 2017 FY | -1.44 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | 213.564% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 98.353% |